{"id":"sl1002","safety":{"commonSideEffects":[{"rate":null,"effect":"Flu-like symptoms"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SL1002 combines human serum albumin with interferon alpha to improve the pharmacokinetic properties and bioavailability of interferon while maintaining its immunostimulatory effects. The fusion protein activates natural killer cells and other components of the innate immune system, making it suitable for treating conditions where enhanced interferon signaling is therapeutically beneficial.","oneSentence":"SL1002 is a recombinant human serum albumin-interferon alpha fusion protein that enhances innate immune responses against viral infections and cancer.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:35:02.019Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection"},{"name":"Melanoma"}]},"trialDetails":[{"nctId":"NCT07226258","phase":"PHASE3","title":"Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain","status":"RECRUITING","sponsor":"Saol Therapeutics Inc","startDate":"2025-11-07","conditions":"Osteoarthritis Knee Pain","enrollment":150},{"nctId":"NCT05311215","phase":"PHASE2","title":"Phase II Study to Assess Safety, Pharmacokinetics and Efficacy of SL-1002 for Limb Spasticity","status":"UNKNOWN","sponsor":"Saol Therapeutics Inc","startDate":"2022-04-22","conditions":"Spasticity","enrollment":32},{"nctId":"NCT05470608","phase":"PHASE2","title":"Phase II Study to Assess Safety and Efficacy of SL-1002 for Osteoarthritic Knee Pain","status":"UNKNOWN","sponsor":"Saol Therapeutics Inc","startDate":"2022-06-13","conditions":"Osteoarthritis, Knee Pain","enrollment":132}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SL1002","genericName":"SL1002","companyName":"Saol Therapeutics Inc","companyId":"saol-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SL1002 is a recombinant human serum albumin-interferon alpha fusion protein that enhances innate immune responses against viral infections and cancer. Used for Chronic hepatitis C virus infection, Melanoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}